Modified Citrus Pectin and Anti-Metastatic Activity

Modified Citrus Pectin and Anti-Metastatic Activity

Metastasis remains one of the most clinically significant aspects of cancer progression, and there is ongoing interest in compounds that may interfere with tumor spread. Glinsky and Raz reviewed the anti-metastatic properties of modified citrus pectin (MCP), a soluble dietary fiber derivative obtained from citrus fruit that has been studied for its biological activity in cancer models.
This work summarizes preclinical evidence suggesting that MCP interacts with galectin-3, a carbohydrate-binding protein implicated in tumor cell adhesion, angiogenesis, immune evasion, and metastatic spread. By binding to galectin-3, MCP is proposed to interfere with multiple steps of the metastatic cascade, including cancer cell aggregation, endothelial adhesion, and establishment of secondary tumor sites.
Experimental studies described in this review show that MCP can reduce cancer cell adhesion to endothelial cells and may inhibit metastatic progression in animal models. These effects are thought to arise from disruption of galectin-3–mediated signaling pathways that contribute to tumor cell survival and dissemination.
Although the evidence is largely derived from in vitro and preclinical studies, the work highlights a biological mechanism through which this dietary-derived compound may influence metastatic behavior. These findings support further investigation into galectin-3 targeting strategies in cancer therapy.

Reference:

Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009;344(14):1788–1791. doi:10.1016/j.carres.2008.08.038. PMID: 19061992; PMCID: PMC2782490.